The United States exempts India and 19 other countries from a planned 100% tariff on certain speciality drugs. The move applies to a defined set of products, with the exemption intended to prevent the full tariff rate from being applied to these medicines for the listed countries.
Outlets report that the exemption is not blanket coverage for all drugs. Instead, it is linked to specific speciality drug categories and individual products under the tariff rules. While the exact scope is described in separate ways by each outlet, both agree that the US policy creates targeted relief for India’s speciality drug supply, alongside similar treatment for other countries.
The differing emphasis across reports is mostly about the framing and coverage—one outlet highlights India among the beneficiaries, while another focuses on “select” Indian speciality drugs. Both accounts indicate that the exemption is part of the broader implementation of the 100% tariff measure, with eligibility determined by product and country.
